Pharmaceutical composition on the basis of Stachytarpheta sp., a process for obtaining the same and its use for treating vitiligo

Abstract

This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plants of the Stachytarpheta (Verbenaceae family) species, as well as roots, stems, barks, and leaves of plants in the form of extracts or enriched fractions, or pure isolated compounds or compounds obtained from synthesis, used alone or mixed with other natural or synthetic products, in different ratios, in order to integrate pharmaceutical compositions to be used by appropriate routes (topic or oral), particularly in the form of tablets, capsules, dyes, emulsions, W/O and O/W (creams and gels), liposomes, microcapsules, nanoparticles, aerosols, ointments, and the like, as well as formulations for slow-release implants, used to treat vitiligo.

1 .- 27 . (canceled) 
     
     
         28 . A method for the prevention and treatment of vitiligo, comprising administering to a mammal in need thereof a composition comprising extracts of one or more parts of the  Stachytarpheta  species, wherein the extracts have one or more compounds, in its free form or in pharmaceutically acceptable salts, from the group of iridoids, flavonoids and ethyl phenyl propane glycosilate derivatives. 
     
     
         29 . The method according to  claim 28 , wherein the compound has both chemical structures I and II of the iridoids group:
 (I) and   wherein R is identical or different and each one is independently selected among H, CH 3 , COCH 3 , alkali metals, halogens, monosaccharides, disaccharides or polysaccharides, CO(CH 2 ) n CH 3 , (CH 2 ) n CH 3 , where n ranges from 2 to 16.   
     
     
         30 . The method according to  claim 28 , wherein the compound has the following chemical structure of the flavonoids group: 
       
         
           
           
               
               
           
         
       
     
     
         31 . The method according to  claim 28 , wherein the compound has the chemical structures IV, V, VI and VII of the ethyl phenyl propane glycosilate derivatives group:
 and   wherein R is identical or different and each one is independently selected among H, CH 3 , CH 2 CH 3 , CH 2 OH, COCH 3 , alkali metals, halogens, monosaccharides, disaccharides or polysaccharides, CO(CH 2 ) n CH 3 , (CH 2 ) n CH 3 , where n ranges from 2 to 16.   
     
     
         32 . The method according to  claim 28 , wherein the extracts are obtained from  Stachytarpheta cayensensis, Stachytarpheta jamaicensis  and  Stachytarpheta eliotis  species, alone or in mixtures. 
     
     
         33 . The method according to  claim 28 , wherein parts of plants of the  Stachytarpheta  genus are stems, roots, barks and leaves. 
     
     
         34 . The method according  claim 29 , wherein the compound of the flavonoid group is Luteolin-7-O-Gluciside. 
     
     
         35 . The method according to  claim 28 , wherein the compounds are in the form pharmaceutically acceptable salts. 
     
     
         36 . The method according to  claim 28 , wherein the composition contains 0.001 to 99% of extracts in weight out of the total weight of the composition. 
     
     
         37 . The method according to  claim 28 , wherein the composition is administered to the mammal at a dose of approximately 0.001 to approximately 5000 mg/kg/day, split into one or more times a day. 
     
     
         38 . The method according to  claim 28 , wherein the composition is administered to the mammal at a dose approximately 200 to approximately 400 mg/kg/day, split into one or more times a day. 
     
     
         39 . The method according to  claim 28 , wherein the composition contains approximately 0.001 mg to 5000 mg of the extract containing one or more compounds. 
     
     
         40 . The method according to  claim 38 , wherein the compound is administered 3 times a day. 
     
     
         41 . The method according to  claim 28 , wherein the compounds are used alone or in combination in the composition. 
     
     
         42 . The method according to  claim 28 , wherein the composition further comprises fixed oils, essential oils, fragrances, powders or excipients from other natural or synthetic origins, drug, vitamin, salt, monosaccharides, disaccharides, polysaccharides, or other pharmaceutically acceptable adjuvants, vehicles or excipients. 
     
     
         43 . The method according to  claim 28 , wherein the composition is in the form of tablets, capsules, dyes, syrups, creams, gels, liposomes, microcapsules, nanoparticles, aerosols, sprays, ointments, injectable liquids, powders, lyophilized, patches, or slow-release implants. 
     
     
         44 . The method according to  claim 28 , wherein the composition is a phytodrug, or a phytotherapic medication. 
     
     
         45 . The method according to  claim 28 , wherein the mammal is human. 
     
     
         46 . The method according to  claim 28 , wherein the composition is orally administered. 
     
     
         47 . The method according to  claim 46 , wherein the composition is a hard gelatinous capsule or a soft gelatinous capsule. 
     
     
         48 . The method according to  claim 47 , wherein the capsules contain from approximately 0.001 mg to approximately 5000 mg of the extract containing one or more compounds.